ReviewPharmaceutical nanotechnology2025
Evolving Advances in the Applications of Carbon Nanotubes (CNTs) for Management of Rheumatoid Arthritis (RA).
Review in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic condition causing joint pain and inflammation that has now spurred the interest in nanotechnology-based drug delivery for more effective treatment, and in this regard, carbon nanotubes (CNTs) are being explored for their potential to deliver the drugs steadily to manage the RA. Many investigators have been investigating both single-walled carbon nanotubes (SWCNT) as well as multi-walled carbon nanotubes (MWCNT) for managing arthritis via targeted drug delivery. Moreover, functionalized CNTs show promise in delivering the drugs precisely and in a controlled manner, thereby minimizing toxicity. However, research on applications of CNTs as drug carriers for RA remains limited, thus necessitating further exploration to address the various challenges. In this present piece of writing, challenges in RA treatment and the advances in applications of CNTs for RA management are reported, consequently reflecting the CNTs as advanced drug delivery vehicles for arthritis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.